| Literature DB >> 34893818 |
Joseph M Rocco1, Christina Mallarino-Haeger2, Attiya H Randolph3, Susan M Ray2, Marcos C Schechter2, Christa S Zerbe1, Steven M Holland1, Irini Sereti1.
Abstract
The development of effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines has been a significant accomplishment. Adverse events are extremely rare, but continued surveillance is important, especially in at-risk populations. In 5 patients with preexisting immune dysregulation, hyperinflammatory syndromes, including hemophagocytic lymphohistiocytosis, developed after SARS-CoV-2 mRNA vaccination. Early recognition of this rare condition is essential. Published by Oxford University Press for the Infectious Diseases Society of America 2021.Entities:
Keywords: COVID-19; Inflammation; Vaccination; hemophagocytic lymphohistiocytosis
Mesh:
Substances:
Year: 2022 PMID: 34893818 PMCID: PMC8689836 DOI: 10.1093/cid/ciab1024
Source DB: PubMed Journal: Clin Infect Dis ISSN: 1058-4838 Impact factor: 20.999